No Signal for Others in Class
JAK ‘Sprat’ Out by Sanofi; Safety Issue Off-Target, Analyst Says
By Randy Osborne
Monday, November 18, 2013
Less than a week after Cell Therapeutics Inc. (CTI) snagged a handsome deal with Baxter International Inc. for its Janus kinase (JAK) inhibitor pacritinib – adding another industry vote for the approach – Sanofi SA disclosed safety problems with its JAK inhibitor fedratinib and ended the Phase III effort, which sparked a new look at the class.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.